Drug Profile
Research programme: platinum derivatives
Alternative Names: Platinum derivatives - research programme Andrulis; Platinum derivatives SAP, poly-plat, SSPLatest Information Update: 20 Sep 2006
Price :
$50
*
At a glance
- Originator Andrulis Pharmaceuticals
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 24 Mar 1999 New profile
- 05 Mar 1999 Preclinical development for Cancer in USA (Unknown route)